Intellia Therapeutics (38I) Price & Analysis

Compare

13 Followers

38I Stock Chart & Stats

€10.96

-€0.50(-4.02%)

At close: Jan 08 4:00 PM EST

€10.96

-€0.50(-4.02%)

Day’s Range― - ―

52-Week Range€5.30 - €24.34

Previous CloseN/A

Volume0.00

Average Volume (3M)612.00

Market Cap

$1.20B

Enterprise Value€1.35B

Total Cash (Recent Filing)$511.04M

Total Debt (Recent Filing)$97.97M

Price to Earnings (P/E)―

Beta1.75

Next Earnings

Feb 19, 2026

EPS Estimate

-0.79

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding115,829,926

10 Day Avg. Volume64

30 Day Avg. Volume612

Financial Highlights & Ratios

PEG Ratio0.71

Price to Book (P/B)1.32

Price to Sales (P/S)19.91

P/FCF Ratio-3.25

Enterprise Value/Market Cap1.12

Enterprise Value/Revenue23.47

Enterprise Value/Gross Profit-63.03

Enterprise Value/Ebitda-2.96

Forecast

1Y Price Target

$13.83

Price Target Upside26.19% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering11

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

HAE Program MomentumThe HAELO Phase III trial for lonvo-z is fully enrolled and exceeded initial expectations, supporting a potential regulatory filing pathway under accelerated review due to a favorable designation.

Key Opinion Leader Safety AssessmentA cardiology key opinion leader judged the reported ATTR-CM patient death likely unrelated to the study drug, attributing it to a perforated ulcer and reducing immediate safety concerns.

Regulatory ProgressFDA lifted the clinical hold on the MAGNITUDE-2 trial after agreement on study expansion and enhanced liver monitoring, allowing enrollment and dosing to resume under more stringent safeguards.

Bears Say

Cardiac Trial UncertaintyThe MAGNITUDE cardiac trial remains on hold and faces greater uncertainty because the cardiac population is older and carries higher baseline liver risk, creating downside risk for program value.

Increased Regulatory Demands And DelaysRegulators may require expanded safety datasets and enhanced early monitoring, which could prompt additional protocol modifications and larger trials that increase development time and costs.

Liver Safety OverhangSerious liver safety events, including a Hy's Law case linked to a patient death, remain a material overhang that could constrain regulatory approvals and market uptake.

Intellia Therapeutics News

Intellia Therapeutics reports inducment grants

Intellia Therapeutics (NTLA) announced that on February 1, 2026, it awarded inducement grants to six new employees under...

13d ago

NTLA

Intellia Therapeutics price target raised to $7 from $4 at Baird’

Baird raised the firm’s price target on Intellia Therapeutics (NTLA) to $7 from $4 and keeps a Neutral...

22d ago

NTLA

Intellia Therapeutics price target raised to $25 from $15 at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Intellia Therapeutics (NTLA) to $25 from $15...

22d ago

NTLA

Citizens says nex-z return to clinic should add ‘significant value’ to Intellia

Citizens analyst Silvan Tuerkcan notes Intellia announced the FDA lifted the nexiguran ziclumeran hold on the ATTRv-PN side,...

23d ago

NTLA

Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!

Investors will find a list of the latest earnings reports, analysts updates, and other stock market news in...

23d ago

Intellia Therapeutics Stock (NTLA) Pops as FDA Lifts Safety Freeze on Nerve Disease Trial

Shares in genome editing group Intellia Therapeutics ($NTLA) rocketed higher today after U.S. regulators lifted a freeze on...

23d ago

NTLA

Intellia up 24% in premarket at $17.34 as FDA lifts hold on nex-z Phase 3 study

08:57 EST Intellia up 24% in premarket at $17.34 as FDA lifts hold on nex-z Phase 3 study...

23d ago

NTLA

Intellia Therapeutics announces FDA lift of clinical hold on MAGNITUDE-2 trial

Intellia Therapeutics (NTLA) announced that the U.S. Food and Drug Administration has removed the clinical hold on the...

23d ago

NTLA

NTLA Upcoming Earnings Report: What to Expect?

Intellia Therapeutics Inc (NTLA) is scheduled to report 4th quarter earnings on 02/19/2026. Regarding Q4 estimates, Wall Street...

2d ago

NTLA

Intellia’s NTLA-2001 Hits Key Milestone in ATTR Gene-Editing Trial, Raising the Stakes in Amyloidosis

Intellia Therapeutics Inc ($NTLA) announced an update on their ongoing clinical study. Study Overview – Intellia Therapeutics is...

20d ago

NTLA

FDA Lifts Hold on Intellia’s MAGNITUDE-2 Trial

Intellia Therapeutics ( ($NTLA) ) just unveiled an update. On January 27, 2026, Intellia Therapeutics announced that the...

23d ago

NTLA

Cathie Wood’s ARK Adds to Intellia Stock (NTLA) — Here’s What Else It Traded This Week

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made just one trade on Thursday, January 15, according to its daily...

1M ago

NTLA

Cathie Wood’s ARK Investment buys 57K shares of Intellia Therapeutics today

20:39 EST Cathie Wood’s ARK Investment buys 57K shares of Intellia Therapeutics (NTLA) today Published first on TheFly...

1M ago

NTLA

Cathie Wood Keeps Loading Up on This Biotech Stock — What’s Driving the Buying Spree?

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) continued to buy shares of Intellia Therapeutics ($NTLA) on Tuesday, extending a...

1M ago

NTLA

38I FAQ

What was Intellia Therapeutics’s price range in the past 12 months?

Intellia Therapeutics lowest stock price was €5.30 and its highest was €24.34 in the past 12 months.

What is Intellia Therapeutics’s market cap?

Intellia Therapeutics’s market cap is $1.20B.

When is Intellia Therapeutics’s upcoming earnings report date?

Intellia Therapeutics’s upcoming earnings report date is Feb 19, 2026 which is today.

How were Intellia Therapeutics’s earnings last quarter?

Currently, no data Available

Is Intellia Therapeutics overvalued?

According to Wall Street analysts Intellia Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Intellia Therapeutics pay dividends?

Intellia Therapeutics does not currently pay dividends.

What is Intellia Therapeutics’s EPS estimate?

Intellia Therapeutics’s EPS estimate is -0.79.

How many shares outstanding does Intellia Therapeutics have?

Intellia Therapeutics has 115,829,926 shares outstanding.

What happened to Intellia Therapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Intellia Therapeutics?

Currently, no hedge funds are holding shares in DE:38I

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Intellia Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-52.11%

Trailing 12-Months

Asset Growth

-21.14%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Intellia Therapeutics

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Intellia Therapeutics (38I) Earnings & Revenues

Historic Earnings Reports

38I Revenue Breakdown

100.00% Collaboration revenue

38I Stock 12 Month Forecast

Average Price Target

€13.83

▲(26.19% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"€4","23":"€23","8.75":"€8.75","13.5":"€13.5","18.25":"€18.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22.79771919,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€22.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.8306163086,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€13.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.91051979,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€5.91</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,8.75,13.5,18.25,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.6,11.538286091538462,12.476572183076922,13.414858274615383,14.353144366153845,15.291430457692307,16.22971654923077,17.16800264076923,18.10628873230769,19.044574823846155,19.982860915384613,20.921147006923075,21.859433098461537,{"y":22.79771919,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.6,10.848508946815384,11.097017893630769,11.345526840446153,11.594035787261538,11.842544734076922,12.091053680892308,12.339562627707693,12.588071574523077,12.836580521338462,13.085089468153846,13.33359841496923,13.582107361784615,{"y":13.8306163086,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.6,10.239270753076923,9.878541506153846,9.51781225923077,9.157083012307693,8.796353765384616,8.435624518461537,8.074895271538463,7.714166024615385,7.353436777692308,6.9927075307692315,6.631978283846154,6.271249036923077,{"y":5.91051979,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.66,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.952,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.234,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.19,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.522,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.56,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.752,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.384,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.85,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.485,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.458,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.6,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >